0001298709-23-000020.txt : 20230912 0001298709-23-000020.hdr.sgml : 20230912 20230912175925 ACCESSION NUMBER: 0001298709-23-000020 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230911 FILED AS OF DATE: 20230912 DATE AS OF CHANGE: 20230912 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Krishnan Krish S CENTRAL INDEX KEY: 0001298709 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38210 FILM NUMBER: 231251170 MAIL ADDRESS: STREET 1: 2100 WHARTON STREET STREET 2: SUITE 701 CITY: PITTSBURGH STATE: PA ZIP: 15203 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Krystal Biotech, Inc. CENTRAL INDEX KEY: 0001711279 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 821080209 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2100 WHARTON STREET STREET 2: SUITE 701 CITY: PITTSBURGH STATE: PA ZIP: 15203 BUSINESS PHONE: (412) 586-5830 MAIL ADDRESS: STREET 1: 2100 WHARTON STREET STREET 2: SUITE 701 CITY: PITTSBURGH STATE: PA ZIP: 15203 4 1 wk-form4_1694555955.xml FORM 4 X0508 4 2023-09-11 0 0001711279 Krystal Biotech, Inc. KRYS 0001298709 Krishnan Krish S C/O KRYSTAL BIOTECH, INC. 2100 WHARTON STREET, SUITE 701 PITTSBURGH PA 15203 1 1 1 0 President and CEO 1 Common Stock 2023-09-11 4 S 0 5008 125.2275 D 1679330 D Common Stock 2023-09-11 4 S 0 5452 126.1677 D 1673878 D Common Stock 2023-09-11 4 S 0 1873 127.1832 D 1672005 D Common Stock 2023-09-11 4 S 0 10557 128.3713 D 1661448 D Common Stock 2023-09-11 4 S 0 2110 129.1013 D 1659338 D Common Stock 2023-09-11 4 S 0 5007 125.2275 D 1619199 I By Spouse Common Stock 2023-09-11 4 S 0 5452 126.1676 D 1613747 I By Spouse Common Stock 2023-09-11 4 S 0 1874 127.1833 D 1611873 I By Spouse Common Stock 2023-09-11 4 S 0 10557 128.3713 D 1601316 I By Spouse Common Stock 2023-09-11 4 S 0 2110 129.1014 D 1599206 I By Spouse Common Stock 90000 I By Krishnan Spousal Trust Common Stock 50000 I By Krishnan Family Trust The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on September 11, 2023 , and will terminate on September 11, 2024, and contemplates sales of 25,000 shares per quarter with a limit price of $100.00 per share. The transaction was executed in multiple trades ranging from $124.7100 to $125.6950. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. The transaction was executed in multiple trades ranging from $125.7200 to $126.6800. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. The transaction was executed in multiple trades ranging from $126.7200 to $127.7100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. The transaction was executed in multiple trades ranging from $127.7350 to $128.7300. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. The transaction was executed in multiple trades ranging from $128.7400 to $129.4200. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Suma Krishnan. The Rule 10b5-1 trading plan started on September 11, 2023 , and will terminate on September 11, 2024, and contemplates sales of 25,000 shares per quarter with a limit price of $100.00 per share. These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Suma Krishnan. Directly beneficially owned by Suma M. Krishnan, the spouse of the Reporting Person. Directly beneficially owned by the Krishnan Family Trust. The Reporting Person and his spouse are each joint beneficial owners of the trust with joint voting and investment control. /s/ Krish S. Krishnan 2023-09-12